Vaxess Technologies, Inc.


Vaxess is transforming healthcare by developing a proprietary transdermal patch and applicator capable of delivering a wide range of therapies and vaccines. Their vision is a needle-free, refrigeration-free future that enables self-administration of vaccines and therapeutics at home or in low-resource settings. The company integrates science from chemistry, biology, immunology, and engineering to create innovative healthcare solutions that are portable and accessible worldwide.

Industries

biotechnology
health-care
medical

Nr. of Employees

medium (51-250)

Vaxess Technologies, Inc.

Cambridge, Massachusetts, United States, North America


Products

Sustained‑release transdermal microarray patch and applicator

A transdermal microarray patch system with dissolvable bioactive tips and a preloaded applicator that deposits slow‑release payloads into the dermal barrier for needle‑free, short‑wear‑time delivery of vaccines and therapeutics.

Formulation and drying platform for biologic stabilization

A matrix formulation and drying approach to stabilize vaccines, diagnostics reagents, and biospecimens for refrigeration‑free storage and transport.

Refrigeration‑free blood collection and stabilization device

A dried sample collection device and stabilization formulation intended to preserve blood analytes for field collection and shipment without refrigeration, compatible with downstream analytical workflows.


Services

GMP contract manufacturing for microarray patches

Production of transdermal microarray patch systems under GMP conditions, including flexible array sizing and device assembly.

Collaborative R&D partnerships for vaccine and therapeutic delivery

Co‑development partnerships with industry and academic groups to apply transdermal sustained‑release delivery and stabilization technologies across vaccine and therapeutic programs.

Expertise Areas

  • Transdermal and microneedle drug/vaccine delivery
  • Biomaterials for biologic stabilization (silk fibroin)
  • Vaccine and biologic thermostability and drying formulations
  • Early‑phase clinical trial management
  • Show More (4)

Key Technologies

  • Transdermal microarray (microneedle) delivery
  • Silk fibroin biomaterial-based formulations
  • Sustained‑release drug delivery
  • Formulation drying/stabilization for cold‑chain reduction
  • Show More (5)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.